BetaShares Global Healthcare ETF (ASX:DRUG) is a good way to invest in defensive shares

BetaShares Global Healthcare ETF (ASX: DRUG) is a good way to invest in a defensive global sector.

What BetaShares Global Healthcare ETF looks to do

The ETF aims to invest in a number of the world’s biggest healthcare businesses which can provide both defensive and growing earnings.

Looking at the portfolio, the top 10 holdings are: Johnson & Johnson, Roche Holding, UnitedHealth Group, Novartis, Merck & Co, Pfizer, Abbott Laboratories, Thermo Fisher Scientific, Eli Lilly and Co and Abbvie.

These businesses are some of the world’s biggest with very entrenched market positions. They specialise in different areas of the healthcare world. The biggest company – Johnson & Johnson – has a few different divisions: consumer health products, medical devices and pharmaceutical products. Many other of the large businesses have useful diversification within their businesses.

As you might expect, around two thirds of this ETF is invested in businesses listed in the US. Then 11.5% is allocated to Swiss healthcare shares, 6.9% is allocated to Japan shares, 5.4% is allocated to UK shares, 3.1% is allocated to French shares,

Fees

BetaShares Global Healthcare ETF has a fairly low cost for how much geographical diversification you get with it. The annual operating cost is just 0.57% per year. Plenty of active Australian fund managers charge annual management fees of 1% per annum.

There are ETFs out there with much lower fees like Vanguard U.S. Total Market Shares Index ETF (ASX: VTS) which has a management fee of just 0.03% per year. So you need to decide if that extra 0.54% per annum is worth getting the specific exposure to these healthcare giants.

ETF performance

BetaShares Global Healthcare ETF isn’t necessarily going to shoot the lights out over the short term or long term. But I think its returns have been reliable. Over the past three years it has returned, after fees, an average of 10.27% per year.

That’s better than the ASX but not as good as ETFs that are invested across every industry. As an Aussie, I’d rather go for something like iShares S&P 500 ETF (ASX: IVV) for my international diversification.

[ls_content_block id=”695″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report, and 24/7 access to the Rask community, for FREE by CLICKING HERE NOW or the button below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.